AB
SNDX icon

Amalgamated Bank’s Syndax Pharmaceuticals SNDX Stock Holding History

Amalgamated Bank’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,677
Closed -$56K – 2650
2025
Q4 		$56K Sell
2,677
-98
-4% -$1.71K ﹤0.01% 1809
2025
Q3 		$43K Hold
2,775
– – ﹤0.01% 1887
2025
Q2 		$26K Hold
2,775
– – ﹤0.01% 2022
2025
Q1 		$34K Buy
2,775
+9
+0.3% +$127 ﹤0.01% 1897
2024
Q4 		$37K Hold
2,766
– – ﹤0.01% 1918
2024
Q3 		$53K Hold
2,766
– – ﹤0.01% 1828
2024
Q2 		$57K Buy
2,766
+106
+4% +$2.22K ﹤0.01% 1828
2024
Q1 		$63K Sell
2,660
-6,128
-70% -$137K ﹤0.01% 1814
2023
Q4 		$190K Sell
8,788
-235
-3% -$3.61K ﹤0.01% 1804
2023
Q3 		$131K Hold
9,023
– – ﹤0.01% 1922
2023
Q2 		$189K Buy
9,023
+2,482
+38% +$51.7K ﹤0.01% 1832
2023
Q1 		$138K Sell
6,541
-607
-8% -$15.1K ﹤0.01% 1933
2022
Q4 		$182K Hold
7,148
– – ﹤0.01% 1895
2022
Q3 		$172K Buy
7,148
+212
+3% +$4.76K ﹤0.01% 1905
2022
Q2 		$133K Buy
6,936
+1,056
+18% +$17.6K ﹤0.01% 2054
2022
Q1 		$102K Buy
+5,880
New +$99K ﹤0.01% 2190

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Amalgamated Bank's SNDX Position: Q1 2026 in Review

Amalgamated Bank sold out of Syndax Pharmaceuticals (SNDX) in Q1 2026, closing a stake of 2,677 shares — an estimated $56K sold.

Amalgamated Bank first reported a position in SNDX in Q1 2022 and held it in 16 quarters. The position peaked at $190K in Q4 2023. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Amalgamated Bank reported no remaining Syndax Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 2,677 Syndax Pharmaceuticals shares in Q1 2026, an estimated $56K.
  • Amalgamated Bank first reported a position in Syndax Pharmaceuticals in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's Syndax Pharmaceuticals position peaked at $190K in Q4 2023.
  • 247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.